Effect of ACE inhibitors on the course of SARS-CoV-2 in a patient with pre-existing chronic kidney disease: a clinical case

Authors

DOI:

https://doi.org/10.22141/2307-1257.12.3.2023.419

Keywords:

SARS-CoV-2-associated nephropathy, renin-angiotensin-aldosterone system, angiotensin-converting enzyme inhibitors, clinical case, chronic kidney disease

Abstract

The presence of in combination with hypertension stage 1–2 and its medical correction using renin-angiotensin-aldosterone system (RAAS) inhibitors significantly affects the health of patients who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses RAAS as a tool to penetrate the cell, namely the receptor of angiotensin-converting enzyme (ACE) 2. The purpose of the work: to assess the dynamics of clinical and laboratory indicators in a patient with SARS-CoV-2-associated nephropathy against the background of taking ACE inhibitors. This article describes a clinical case from the author’s own practice. Timely prescription of etiotropic therapy for coronavirus disease 19 significantly reduces complications of chronic kidney disease course with hypertension.

Downloads

Download data is not yet available.

References

Zavalna IM. Renal function in patients with chronic kidney disease and hypertension degree 1-2 against the background of SARS-CoV-2. Pocki. 2023;12(1):15-25. doi:10.22141/2307-1257.12.1.2023.390. (in Ukrainian).

Ivanov DD, Gozhenko AI, Ivanova MD, Zavalna IN, Crestanello T. The dynamics of hypertension and renal function in CKD and non- -CKD patients affected with COVID-19 - final results of BIRCOV trial. Eur J Clin Exp Med. 2023;21(2):230-238. doi:10.15584/ ejcem.2023.2.3.

Gressens SB, Leftheriotis G, Dussaule JC, Flamant M, Levy BI, Vidal-Petiot E. Controversial roles of the renin angiotensin system and its modulators during the COVID-19 pandemic. Front Physiol. 2021 Feb 22;12:624052. doi:10.3389/fphys.2021.624052.

Coto E, Avanzas P, Gomez J. The Renin-Angiotensin-Aldosterone System and Coronavirus Disease 2019. Eur Cardiol. 2021 Mar 9;16:e07. doi:10.15420/ecr.2020.30.

Rieder M, Wirth L, Pollmeier L, et al. Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19. Am J Hypertens. 2021 Apr 2;34(3):278-281. doi:10.1093/ajh/hpaa169.

Costa LB, Perez LG, Palmeira VA, et al. Insights on SARS-CoV-2 Molecular Interactions With the Renin-Angiotensin System. Front Cell Dev Biol. 2020 Sep 16;8:559841. doi:10.3389/fcell.2020.559841.

Azinheira Nobrega Cruz N, Goncalves de Oliveira LC, Tedesco Silva Junior H, Osmar Medina Pestana J, Casarini DE. Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients. Front Physiol. 2021 Aug 23;12:700220. doi:10.3389/fphys.2021.700220.

Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. COVID-19 and the kidney: what we think we know so far and what we don't. J Nephrol. 2020 Dec;33(6):1213-1218. doi:10.1007/s40620-020-00789-y.

Hardenberg JB, Stockmann H, Aigner A, et al. Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. Kidney Int Rep. 2021 Apr;6(4):905-915. doi:10.1016/j.ekir.2021.01.011.

Shukla AK, Banerjee M. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi:10.1007/s40292-021-00439-9.

Beyerstedt S, Casaro EB, Rangel EB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919. doi:10.1007/s10096-020-04138-6.

Alexandre J, Cracowski JL, Richard V, Bouhanick B; Drugs, COVID-19 working group of the French Society of Pharmacology, Therapeutics. Renin-angiotensin-aldosterone system and COVID-19 infection. Ann Endocrinol (Paris). 2020 Jun;81(2-3):63-67. doi:10.1016/j.ando.2020.04.005.

Albashir AAD. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19). South Med J. 2021 Jan;114(1):51-56. doi:10.14423/SMJ.0000000000001200.

Alcocer-Diaz-Barreiro L, Cossio-Aranda J, Verdejo-Paris J, et al. COVID-19 and the renin, angiotensin, aldosterone system. A complex relationship. Arch Cardiol Mex. 2020;90(Supl):19-25. doi:10.24875/ACM.M20000063.

Khazaal S, Harb J, Rima M, et al. The Pathophysiology of Long COVID throughout the Renin-Angiotensin System. Molecules. 2022 May 2;27(9):2903. doi:10.3390/molecules27092903.

Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020 Jul;251(3):228-248. doi:10.1002/path.5471.

Ivanov DD, Gozhenko AI, Ivanova MD, Zavalna IN. Effect of COVID-19 on kidney function in patients with arterial hypertension grade 1-2 and CKD. Nephrology (Saint-Petersburg). 2022;26(1):34-43. doi:10.24884/1561-6274-2022-26-1-34-43. (in Russian).

Curran CS, Rivera DR, Kopp JB. COVID-19 Usurps Host Regulatory Networks. Front Pharmacol. 2020 Aug 14;11:1278. doi:10.3389/fphar.2020.01278.

Downloads

Published

2023-09-18

How to Cite

Zavalna, I. (2023). Effect of ACE inhibitors on the course of SARS-CoV-2 in a patient with pre-existing chronic kidney disease: a clinical case. KIDNEYS, 12(3), 157–160. https://doi.org/10.22141/2307-1257.12.3.2023.419

Issue

Vol. 12 No. 3 (2023)

Section

Clinical Observation

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.